The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical trial stages, the first COVID-19 mRNA vaccine was administered on 8 December ...
A multi-disciplinary research team at the Wyss Institute at Harvard University, Dana-Farber Cancer Institute, and ...
Machine learning reveals unique COVID vaccine immune signatures in people living with HIV, with differences in antibodies, cytokines, and T cell responses.
The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical trial stages, the first COVID-19 mRNA vaccine was administered on 8 December ...
The study offers one of the most detailed maps yet of how human antibody responses vary from person to person.
Wyss Institute's DoriVac combined vaccine and adjuvant technology uses nanoscale precision enabled by DNA origami to induce broad immunity against ...
Creating a clear and well-defined bioanalytical methodology to quantify humoral and cellular immune responses is critical for ...
The AIM-listed immunotherapy specialist will present three posters at the AAAAI Annual Meeting in Philadelphia this week Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU), the AIM-listed ...
Since the program’s authorization in May 2025, between prior repurchases and the ASR, ADMA will have repurchased approximately $160 million of its common stock to date. Management believes these ...
ADMA posts 18% Q4 revenue growth as Asceniv drives record 2025 sales, with 2026 revenues seen topping $635M and margins set to expand.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results